Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Type 1 Diabetes
Diamyd(R) Study Published in Prestigious New England Journal of Medicine
October 22nd, 2008
Diamyd Medical reports that the world's most influential medical journal, the New England Journal of Medicine, has published an article with results from the company's study of the Diamyd(R) diabetes vaccine for type 1 diabetes. The article is now available on the journal's web site and will be in print on October 30. It presents the results of the concluded Phase II study of the Diamyd(R) diabetes vaccine. The article provides detailed information about the study, which showed that Diamyd(R) helped children and adolescents with type 1 diabetes, who participated in the study, retain the ability to produce their own insulin without causing any...
Source: Vaccine Weekly (2008-10-22)
|
